Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dean Tsarwhas"'
Autor:
Ami N Shah, Lisa Flaum, Irene Helenowski, Cesar A Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy.Methods We conducted a single-arm, ph
Externí odkaz:
https://doaj.org/article/8f13f23e68dd4f8e940351b6de1ccf17
Autor:
Lorenzo Gerratana, Michael Movarek, Firas Wehbe, Neelima Katam, Devalingam Mahalingam, Jeannine Donahue, Ami Shah, Young K. Chae, Mary Mulcahy, Dean Tsarwhas, Victoria Villaflor, Aparna Kalyan, Maha Hussein, Jyoti Patel, Sunandana Chandra, Leonidas C. Platanias, William Gradishar, Massimo Cristofanilli, Amir Behdad
Publikováno v:
JCO precision oncology. 6
PURPOSE Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for baseline characterization and longitudinal monitoring of a tumor throughout disease management. The aim of this study was to evaluate the utility of ctDNA acro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6605566558742ea6784a888881e876eb
https://pubmed.ncbi.nlm.nih.gov/35772051
https://pubmed.ncbi.nlm.nih.gov/35772051
Autor:
Alain Mina, Carlos Galvez, Reem Karmali, Mary Mulcahy, Xinlei Mi, Masha Kocherginsky, Michael J Gurley, Neelima Katam, William Gradishar, Jessica K Altman, Michael G Ison, Dean Tsarwhas, Christopher George, Jane N Winter, Leo I. Gordon, Firas H Wehbe, Leonidas C Platanias
Publikováno v:
Cancers; Volume 14; Issue 9; Pages: 2209
Patients with a history of malignancy have been shown to be at an increased risk of COVID-19-related morbidity and mortality. Poorer clinical outcomes in that patient population are likely due to the underlying systemic illness, comorbidities, and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac459750d9a2905245bc9a91d8669c4d
https://pubmed.ncbi.nlm.nih.gov/35565336
https://pubmed.ncbi.nlm.nih.gov/35565336
Autor:
Sarika Jain, Valerie Nelson, Massimo Cristofanilli, Lisa Flaum, Ami N. Shah, Cesar A. Santa-Maria, William J. Gradishar, Dean Tsarwhas, Alfred Rademaker, Irene Helenowski
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundResponse rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy.MethodsWe conducted a single-arm, phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5bb1149eebfb7aaa5ea129a428e1a91
https://doi.org/10.1136/jitc-2019-000173
https://doi.org/10.1136/jitc-2019-000173
Autor:
Cesar A. Santa-Maria, Alfred Rademaker, Sarika Jain, Dean Tsarwhas, Tara Dedic, Ami N. Shah, Valerie Nelson, Lisa Flaum, Massimo Cristofanilli, Regina Uthe, William J. Gradishar, Irene Helenowski, Kelly Kindy
Publikováno v:
Journal of Clinical Oncology. 37:1096-1096
1096 Background: Response rates to single agent immune checkpoint blockade in unselected MBC are low; however, they may be augmented when combined with chemotherapy. Methods: We conducted a single-arm, phase II study of patients with TN or endocrine-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::653a4c5f31e3e306e1608f2ae4ca8ea9
https://doi.org/10.1200/jco.2019.37.15_suppl.1096
https://doi.org/10.1200/jco.2019.37.15_suppl.1096
Autor:
Angel G. Galvez, Jacob D. Bitran, Kathy Tolzien, Steven Newman, Dean Tsarwhas, Chadi Nabhan, Susan K. Kelby, Timothy M. Lestingi
Publikováno v:
Urology. 74:665-671
Objectives To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive castration-resistant prostate cancer. Methods Eligible patients received erlotinib at 150 mg daily until disease progression. Toxicity was assessed ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3a168a9d1564047ca673e9d4e539e5
https://doi.org/10.1016/j.urology.2009.05.016
https://doi.org/10.1016/j.urology.2009.05.016